Anatara Lifesciences Ltd

ASX:ANR ISIN:AU000000ANR0

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(R) is a natural plant based product that aids in the control of diarrhoea and will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.

     

News

Anatara Lifesciences Ltd (ASX:ANR) CEO, Dr Mel Bridges Announces Retirement

🕔5/17/2018 8:30:21 AM 1685

Anatara Lifesciences Ltd (ASX:ANR) announces that Executive Chairman, Dr Mel Bridges has informed the Board of his wish to retire from his role at Anatara with immediate effect and the Board has formally accepted his resignation.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation on Zoetis Exclusive Global License

🕔5/16/2018 1:39:11 PM 1477

Anatara Lifesciences (ASX:ANR) is pleased to release a new investor presentation following the announcement that Anatara had established an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach(R).

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Exclusive Global License Agreement with Zoetis

🕔5/15/2018 9:50:29 AM 1751

Anatara Lifesciences (ASX:ANR) is delighted to announce an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach(R) as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Quarterly Report

🕔4/19/2018 8:27:06 AM 1965

Anatara Lifesciences (ASX:ANR) today released its Appendix 4C financial report for the quarter ending 31st March 2018.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Half Yearly Report

🕔2/22/2018 9:13:31 AM 2417

Anatara Lifesciences (ASX:ANR) today released its Appendix 4D financial report for the half year ending 31st December 2017.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Achieves a Major US FDA Milestone in the Registration of Detach(R) with Approval of the Human Food Safety Dossier

🕔2/5/2018 8:29:16 AM 3183

Anatara Lifesciences (ASX:ANR) has achieved a significant milestone in the United States of America after receiving a "complete" letter from the US Food and Drug Administration for the Technical Section of its Human Food Safety submission. The HFS is a major component of a New Animal Drug Application which is currently underway and is necessary for enabling the marketing of Detach(R) in the US.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Receives $1.23m R&D Tax Refund

🕔1/18/2018 9:38:13 AM 3185

Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $1,230,329 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive scheme.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Presents at Australasian Pig Science Association Conference

🕔11/21/2017 3:38:26 PM 2331

At the Australasian Pig Science Association Conference in Melbourne this week, Dr Trish Holyoake & Dr Tracey Mynott presented a poster highlighting the comparable efficacy of a single dose of Anatara's (ASX:ANR) Detach(R) product to in-feed Zinc oxide in reducing diarrhoea and antibiotic treatments in post-weaning piglets.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Chairman's Address to Shareholders

🕔11/13/2017 11:44:04 AM 2640

Anatara Lifesciences Ltd (ASX:ANR) provides the Chairman's address to shareholders.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Dr Tracey Mynott Presents at TRI Science Business Inspiration Series

🕔11/3/2017 12:11:11 PM 2739

Anatara Lifesciences (ASX:ANR) CSO, Dr Tracey Mynott, was recently invited to present at the Translational Research Institute's Science Business Inspiration Series. The series was launched with Session 1 "The whole journey: from idea to reality".

Read Full Article
###

27,119 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 39) (Last 30 Days: 185) (Since Published: 27119) 

Markets ASX:ANR

Company Data

    Headquarters
  • 433 Logan Road, Stones Corner
    Brisbane, Queensland 4120
    Australia
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.anataralifesciences.com
  • E:
  • info@anataralifesciences.com

Company Reports

Presentations

Research Report

Quarterly Report

Social Media